Anbio Biotechnology (NNNN) Fundamentals 2026 — P/E 47.9x, Revenue Analysis | SniperIQ
Anbio Biotechnology (NNNN) is a DE-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of $406M, trading at $9.26 on the NASDAQ. This SniperIQ fundamentals page covers Anbio Biotechnology's valuation (P/E 47.9x, P/B 13.5x), profitability (net margin 72.1%), revenue ($9M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Anbio Biotechnology's market cap?
Anbio Biotechnology (NNNN) has a market capitalization of approximately $406M, trading at $9.26 on the NASDAQ. Market cap moves with the live share price.
What is Anbio Biotechnology's P/E ratio?
Anbio Biotechnology's trailing twelve-month P/E ratio is 47.9x, with a price-to-book (P/B) of 13.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Anbio Biotechnology?
Anbio Biotechnology runs a net profit margin of 72.1%, a gross margin of 86.1%, and an operating margin of 65.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Anbio Biotechnology generate?
Anbio Biotechnology reported revenue of $9M for fiscal year 2025, with net income of $6M and earnings per share (EPS) of 0.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Anbio Biotechnology pay a dividend?
Anbio Biotechnology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Anbio Biotechnology financially healthy?
Anbio Biotechnology carries a debt-to-equity ratio of 0.00x and a current ratio of 344.31x, with a market beta of 5.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Anbio Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Anbio Biotechnology (NNNN) the key facts are: market cap $406M, P/E 47.9x, revenue $9M, 52-week range 8.3-54.95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Anbio Biotechnology's full fundamentals live
Get Anbio Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.